Thomas Jahn

Thomas Jahn currently serves as the VP of Target & Drug Discovery at CardiaTec Bio, starting in April 2025, where the focus is on integrating AI and systems biology into cardiovascular therapeutics. Previously, Thomas was the Senior Director - Head of Discovery Biology Germany at Dewpoint Therapeutics from March 2021 to March 2025, responsible for building a discovery biology team and guiding strategic drug discovery programs. Thomas's experience at AbbVie, spanning from December 2015 to February 2021, included roles as Principal Research Scientist II and Principal Research Scientist, leading initiatives in neurodegenerative disease and collaborating with external partners. Prior to AbbVie, Thomas founded a research group at the University of Heidelberg and DKFZ, focusing on proteostasis in neurodegenerative diseases, and conducted postdoctoral research at the University of Cambridge on neurodegenerative disease models. Thomas holds a Diplom in Biochemistry from The Martin Luther University of Halle-Wittenberg and completed a PhD in Structural Biology of Protein Misfolding at the University of Leeds.